{"id":"NCT04201262","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD","officialTitle":"A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-10","primaryCompletion":"2022-03-15","completion":"2024-11-01","firstPosted":"2019-12-17","resultsPosted":"2023-08-09","lastUpdate":"2024-12-31"},"enrollment":58,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica","Neuromyelitis Optica Spectrum Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","Ultomiris"]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.","primaryOutcome":{"measure":"Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period","timeFrame":"Baseline up to 2.25 years (end of the Primary Treatment Period)","effectByArm":[{"arm":"Ravulizumab","deltaMin":0,"sd":null},{"arm":"Placebo (ECU-NMO-301)","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":41,"countries":["United States","Australia","Austria","Canada","Denmark","France","Germany","Italy","Japan","Poland","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["38356884"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":58},"commonTop":["Headache","Urinary tract infection","Nausea","COVID-19","Back pain"]}}